New pathways discovered for drugs to act on cells
Previously unknown access points in cell membrane proteins have been discovered, enabling laboratory-developed drugs to modify cell function
- Date:
- March 27, 2025
- Source:
- IMIM (Hospital del Mar Medical Research Institute)
- Summary:
- Previously unknown access points in cell membrane proteins have been discovered, enabling laboratory-developed drugs to modify cell function. The discovery was made possible through computer simulations with an unprecedented level of detail. The results are available online to support the development of new, targeted drugs for a wide range of diseases.
- Share:
Cell membrane proteins hide secret gateways that can be used to modify cell behavior. This has been demonstrated in a study led by the Hospital del Mar Research Institute and published in Nature Communications, with participation from research centers in Spain, Switzerland, the United Kingdom, Germany, France, Poland, the Netherlands, Denmark, Hungary, Italy, Sweden, China, and the United States. The findings may facilitate the creation of new medications or improve the mechanisms of existing ones.
The study's findings are based on computer simulations that achieved an unprecedented level of detail. Researchers were able to observe, at atomic scale and in real time, how membrane lipids interact with G protein-coupled receptors (GPCRs) in their natural environment. These interactions reveal new ways to modulate cellular functions that would otherwise remain invisible. "We have discovered new gateways for drugs to modulate proteins that regulate cellular activity," explains Dr. Jana Selent, coordinator of the GPCR Drug Discovery Research Group within the Biomedical Informatics Research Program (GRIB) at the Hospital del Mar Research Institute, a joint group with Pompeu Fabra University.
GPCRs are important because a significant portion of existing drugs target them to act on cells. In fact, 34% of FDA-approved drugs are based on these receptors. "Having detailed information about the specific site where these drugs act within the cell will accelerate the development of targeted therapies," adds Dr. Selent.
Work in Progress
Although the study published is based on data from 190 experiments covering 60% of known GPCRs, the work continues to uncover the mechanisms used by these proteins to regulate cell function. So far, researchers have confirmed that beyond the known access points, there are others only visible through computer simulations. These newly identified pathways could be leveraged to develop innovative therapeutic treatments. According to Dr. David Aranda, postdoctoral researcher at GRIB and lead author of the study, these are "more specific gateways for each receptor -- a more direct way to modulate cell behavior."
In many cases, it was known that a drug acted on cells, but not how. These results shed light on this aspect of cellular dynamics, making it possible to identify "targets that help create more selective, more precise medications, thereby reducing possible side effects. This could allow us to go beyond current methods used in treating multiple conditions," he adds.
This information, along with future findings, is freely available for use by any laboratory working on developing or improving medications.
Story Source:
Materials provided by IMIM (Hospital del Mar Medical Research Institute). Note: Content may be edited for style and length.
Journal Reference:
- David Aranda-García, Tomasz Maciej Stepniewski, Mariona Torrens-Fontanals, Adrian García-Recio, Marta Lopez-Balastegui, Brian Medel-Lacruz, Adrián Morales-Pastor, Alejandro Peralta-García, Miguel Dieguez-Eceolaza, David Sotillo-Nuñez, Tianyi Ding, Matthäus Drabek, Célien Jacquemard, Jakub Jakowiecki, Willem Jespers, Mireia Jiménez-Rosés, Víctor Jun-Yu-Lim, Alessandro Nicoli, Urszula Orzel, Aida Shahraki, Johanna K. S. Tiemann, Vicente Ledesma-Martin, Francho Nerín-Fonz, Sergio Suárez-Dou, Oriol Canal, Gáspár Pándy-Szekeres, Jiafei Mao, David E. Gloriam, Esther Kellenberger, Dorota Latek, Ramon Guixà-González, Hugo Gutiérrez-de-Terán, Irina G. Tikhonova, Peter W. Hildebrand, Marta Filizola, M. Madan Babu, Antonella Di Pizio, Slawomir Filipek, Peter Kolb, Arnau Cordomi, Toni Giorgino, Maria Marti-Solano, Jana Selent. Large scale investigation of GPCR molecular dynamics data uncovers allosteric sites and lateral gateways. Nature Communications, 2025; 16 (1) DOI: 10.1038/s41467-025-57034-y
Cite This Page: